Trial Profile
Tumour response markers and overall survival in advanced melanoma patients treated with PD-1 inhibitor pembrolizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2016
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 22 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology